All In Biotech

Drug Trial Radar · NCT07660731

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

A PHASE 1 STUDY TO EVALUATE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, FOOD EFFECT, METABOLISM & EXCRETION, AND DRUG-DRUG INTERACTION POTENTIAL OF PF-08103402 IN HEALTHY ADULTS AND/OR ADULTS WITH MILD TO MODERATE ASTHMA

Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 133 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

133

Planned (sponsor's estimate)

Start

Jun 17, 2026

Primary completion

Mar 30, 2027

Study completion Mar 30, 2027

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 22, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Sequential
Masking
Double (participant, investigator)
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to learn about the safety of a new study medicine called PF-08103402 in healthy adults (do not have disease) and or in adults with mild-to-moderate asthma. This is the first time the study medicine is being given to people. For Parts A, B, C, D and F, the study is seeking participants who: * Are healthy (do not have disease) males or females who can no longer have children, * Are 18 to 65 years old, * Have a body mass index (BMI) of 16 to 32 kilograms per meter squared and a body weight of more than 50 kilograms (110 pounds). Body mass index is a way to measure body fat by using a person's height and weight For Part A (optional group or cohort 3: Japanese participants only): * A body weight of more than 45 kilograms (100 pounds). * Have 4 biological Japanese grandparents who were born in Japan. For Part E only: * Adults with a documented history of asthma (confirmed by a doctor) for at least 12 months before entering the study. * Have a body mass index (BMI) of 16 to 35 kilograms per meter squared and a total body weight of more than 50 kilograms (110 pounds). The study has six parts: Part A, Part B, Part C, Part D, Part E and Part F. The study medicine will be taken as a suspension or tablet by mouth 1 time a day (except in Parts B and E where it will be taken 1 time a day for 14 days) at the study clinic. The study will help understand: * how the body processes the study medicine in healthy participants (Parts A and B), * how much of the study medicine gets into the bloodstream and if food affects the amount of study medicine in the blood in healthy participants (Part C), * how the study medicine is broken down and leaves the body in healthy participants (Optional Part D), * how the study medicine is processed in adults with mild-to-moderate asthma (Optional Part E), * if taking the study medicine together with another medicine affects how each medicine is processed by the body in healthy participants (Optional Part F). Participants will take part in the study for about 10 weeks (Parts A and F), 12 weeks (Part B), 9 weeks (Parts C and D), and 16 weeks (Part E). During this time, they will have 2 study visits at the study clinic and up to 28 overnight stays (Part A), 18 overnight stays (Parts B and E), 10 overnight stays (Part C), 11 overnight stays (Part D), and 16 overnight stays (Part F). The study team will also call participants 1 time over the phone at the end of the study to assess how they are doing. Study measurements will be taken by body examination, monitoring side effects, blood and urine tests, heart tests (ECG), vital signs (blood pressure, pulse and respiratory rate), questionnaires (Parts C and E), stool samples (Part D only), and breathing tests (Part E only).

Conditions

  • Healthy Volunteer Study
  • Healthy Adults
  • Healthy Participants
  • Asthma

Interventions

  • PF-08103402Drug

    Oral suspension (Parts A to F); Tablets (Parts C and F only)

  • PlaceboDrug

    Oral suspension (Parts A, B and E).

  • MidazolamDrug

    Oral syrup

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants with Treatment Emergent Adverse Events (TEAEs)Time frame: Parts A: Up to Day 36; Part B and E: Up to Day 50
  2. Number of Participants with Serious Adverse Events (SAEs)Time frame: Parts A: Up to Day 36; Part B and E: Up to Day 50
  3. Number of Participants With Clinically Significant Change From Baseline in Laboratory AbnormalitiesTime frame: Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17
  4. Number of Participants With Clinically Significant Change From Baseline in Vital SignsTime frame: Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17
  5. Number of Participants With Clinically Significant Change From Baseline in Electrocardiogram (ECG) FindingsTime frame: Parts A: Change From Baseline to Day 7; Part B and E: Change From Baseline to Day 17
  6. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise (AUClast) in the fasted stateTime frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1
  7. Maximum observed plasma concentration (Cmax) in the fasted stateTime frame: Pre-dose (Hour 0) and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1
  8. Total recovery of drug-related material in urine and feces separately, and both routes combined, expressed as a percent of total dose administeredTime frame: Pre-dose (Hour 0) and at 1.5, 2, 3, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)
  9. Maximum observed plasma concentration (Cmax)Time frame: Pre-dose (Hour 0) and at 0.5, 1, 2, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)
  10. Area under the curve from time zero to extrapolated infinite time (AUCinf) if data permit, otherwise AUClastTime frame: Pre-dose (Hour 0) and at 0.5, 1, 2, 4, 6, 8, 12 hours post-dose on Day 1 and at 24 hours post-dose (Day 2)

Locations

2 sites in 2 countries. Site status is shown where the registry gives one.

  • Pfizer Clinical Research Unit - New Haven

    New Haven, Connecticut · Recruiting

  • Pfizer Clinical Research Unit - Brussels

    Brussels, Belgium · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.